{"url_path":"/sec/derm/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-060297-index.html","accession_number":"0001104659-26-060297","cik":"0001867066","ticker":"DERM","issuer_name":"Journey Medical Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-060297-index.html","primary_entity_key":"0001867066","primary_entity_name":"Journey Medical Corp"},"word_count":632,"has_tables":true,"body_markdown":"Journey Medical Corp_March 31, 2026\n\nhttp://fasb.org/us-gaap/2025#RelatedPartyMember0001867066--12-312026Q1false0000Journey Medical Corphttp://fasb.org/us-gaap/2025#RelatedPartyMember1000000002000000003000000004000000005000000001000000020000000300000004000000050000000P3YP4Y0001867066us-gaap:CommonStockMember2026-01-012026-03-310001867066us-gaap:CommonStockMember2025-01-012025-03-310001867066us-gaap:RetainedEarningsMember2026-03-310001867066us-gaap:AdditionalPaidInCapitalMember2026-03-310001867066us-gaap:RetainedEarningsMember2025-12-310001867066us-gaap:AdditionalPaidInCapitalMember2025-12-310001867066us-gaap:RetainedEarningsMember2025-03-310001867066us-gaap:AdditionalPaidInCapitalMember2025-03-310001867066us-gaap:RetainedEarningsMember2024-12-310001867066us-gaap:AdditionalPaidInCapitalMember2024-12-310001867066us-gaap:CommonClassAMemberus-gaap:CommonStockMember2026-03-310001867066us-gaap:CommonStockMember2026-03-310001867066us-gaap:CommonClassAMemberus-gaap:CommonStockMember2025-12-310001867066us-gaap:CommonStockMember2025-12-310001867066us-gaap:CommonClassAMemberus-gaap:CommonStockMember2025-03-310001867066us-gaap:CommonStockMember2025-03-310001867066us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-12-310001867066us-gaap:CommonStockMember2024-12-310001867066us-gaap:EmployeeStockOptionMember2025-01-012025-12-310001867066us-gaap:EmployeeStockOptionMember2025-12-310001867066derm:StockPlan2015Member2026-03-310001867066derm:EmployeeStockPurchasePlan2023Member2026-03-310001867066derm:StockPlan2015Member2024-06-242024-06-240001867066derm:StockPlan2015Member2024-06-232024-06-230001867066us-gaap:RestrictedStockUnitsRSUMember2025-12-310001867066srt:MinimumMemberus-gaap:EmployeeStockOptionMember2026-01-012026-03-310001867066srt:MaximumMemberus-gaap:EmployeeStockOptionMember2026-01-012026-03-310001867066us-gaap:OperatingSegmentsMember2026-01-012026-03-310001867066us-gaap:OperatingSegmentsMember2025-01-012025-03-310001867066derm:QbrexzaMember2026-01-012026-03-310001867066derm:OtherLegacyMember2026-01-012026-03-310001867066derm:FoamFranchiseProductsAmzeeqZilxiMember2026-01-012026-03-310001867066derm:EmrosiMember2026-01-012026-03-310001867066derm:AccutaneMember2026-01-012026-03-310001867066derm:QbrexzaMember2025-01-012025-03-310001867066derm:OtherLegacyMember2025-01-012025-03-310001867066derm:FoamFranchiseProductsAmzeeqZilxiMember2025-01-012025-03-310001867066derm:EmrosiMember2025-01-012025-03-310001867066derm:AccutaneMember2025-01-012025-03-310001867066derm:FortressMemberderm:SharedServicesAgreementWithFortressMember2026-01-012026-03-310001867066derm:FortressMemberderm:SharedServicesAgreementWithFortressMember2025-01-012025-03-310001867066derm:TermLoanMemberderm:SwkFundingLlcMember2024-11-252024-11-250001867066derm:TermLoanMemberderm:SwkFundingLlcMember2024-06-262024-06-260001867066derm:FortressMemberderm:SharedServicesAgreementWithFortressMember2026-03-310001867066derm:FortressMemberderm:SharedServicesAgreementWithFortressMember2025-12-310001867066derm:AmzeeqMemberderm:CutiaLicenseAgreementMember2026-01-012026-03-310001867066derm:AmzeeqMemberderm:CutiaLicenseAgreementMember2024-11-112024-11-1100018670662024-07-012024-07-310001867066us-gaap:RetainedEarningsMember2026-01-012026-03-310001867066derm:DermatologicalSegmentMember2026-01-012026-03-310001867066us-gaap:RetainedEarningsMember2025-01-012025-03-310001867066derm:DermatologicalSegmentMember2025-01-012025-03-310001867066derm:TermLoanMemberderm:SwkFundingLlcMember2024-07-0800018670662024-07-310001867066srt:MinimumMember2026-03-310001867066srt:MaximumMember2026-03-310001867066srt:MinimumMember2025-12-310001867066srt:MaximumMember2025-12-310001867066us-gaap:RestrictedStockUnitsRSUMember2026-03-310001867066us-gaap:EmployeeStockOptionMember2026-03-310001867066derm:EmployeeStockPurchasePlanMember2026-03-310001867066us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001867066derm:TermLoanMemberderm:SwkFundingLlcMember2026-03-310001867066derm:TermLoanMemberderm:SwkFundingLlcMember2023-12-272023-12-270001867066us-gaap:CommonClassAMember2026-03-310001867066derm:CommonExcludingClassMember2026-03-310001867066us-gaap:CommonClassAMember2025-12-310001867066derm:CommonExcludingClassMember2025-12-310001867066derm:EmployeeStockPurchasePlan2023Member2023-12-3100018670662024-12-310001867066us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001867066us-gaap:FairValueMeasurementsRecurringMember2026-03-310001867066us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001867066us-gaap:FairValueMeasurementsRecurringMember2025-12-310001867066us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001867066us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001867066us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001867066us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001867066us-gaap:CostOfGoodsTotalMember2026-01-012026-03-310001867066us-gaap:CostOfGoodsTotalMember2025-01-012025-03-310001867066us-gaap:SellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001867066us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001867066us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001867066us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001867066us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001867066us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001867066us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001867066us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001867066derm:EmrosiAgreementMember2021-06-292021-06-290001867066derm:EmployeeStockPurchasePlanMember2026-01-012026-03-310001867066derm:TermLoanMemberderm:ThirdAmendmentMemberderm:SwkFundingLlcMember2025-09-250001867066derm:ZilxiMember2022-01-012022-01-310001867066derm:AmzeeqMember2022-01-012022-01-310001867066derm:TermLoanMemberderm:ThirdAmendmentMemberderm:SwkFundingLlcMember2025-09-252025-09-250001867066derm:TermLoanMemberderm:ThirdAmendmentMemberderm:SwkFundingLlcMember2025-09-242025-09-240001867066derm:TermLoanMemberderm:ThirdAmendmentMemberderm:SwkFundingLlcMember2025-01-012025-12-3100018670662025-08-3100018670662026-01-150001867066derm:TermLoanMemberderm:SwkFundingLlcMember2024-07-090001867066derm:AmzeeqMemberderm:CutiaLicenseAgreementMember2024-11-110001867066derm:EmrosiAgreementMember2024-04-012024-04-300001867066derm:VyneProductAcquisitionAgreementMember2022-01-310001867066derm:EmrosiAgreementMember2024-12-012024-12-310001867066srt:MinimumMemberderm:EmrosiAgreementMember2021-06-292021-06-290001867066srt:MaximumMemberderm:EmrosiAgreementMember2021-06-292021-06-290001867066derm:EmrosiAgreementMember2021-06-2900018670662025-01-012025-03-3100018670662025-03-310001867066us-gaap:RestrictedStockUnitsRSUMember2024-07-092024-07-090001867066derm:TermLoanMemberderm:SwkFundingLlcMember2023-12-270001867066derm:TermLoanMemberderm:SwkFundingLlcMember2026-01-012026-03-310001867066derm:CustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001867066derm:CustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001867066derm:CustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001867066derm:CustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001867066derm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:EliLillyAndCompanyMemberderm:QbrexzaMemberderm:AssetPurchaseAgreementMember2021-03-012021-03-310001867066derm:QbrexzaMembersrt:MinimumMemberderm:RoyaltyPaymentPercentageForThereafterMemberderm:AssetPurchaseAgreementMember2021-03-012021-03-310001867066derm:QbrexzaMembersrt:MinimumMemberderm:RoyaltyPaymentPercentageForFirstTwoYearsMemberderm:AssetPurchaseAgreementMember2021-03-012021-03-310001867066derm:QbrexzaMembersrt:MaximumMemberderm:RoyaltyPaymentPercentageForThereafterMemberderm:AssetPurchaseAgreementMember2021-03-012021-03-310001867066derm:QbrexzaMembersrt:MaximumMemberderm:RoyaltyPaymentPercentageForFirstTwoYearsMemberderm:AssetPurchaseAgreementMember2021-03-012021-03-310001867066derm:QbrexzaMemberderm:RoyaltyPaymentPercentageForFirstTwoYearsMemberderm:AssetPurchaseAgreementMember2021-03-012021-03-310001867066derm:EliLillyAndCompanyMemberderm:QbrexzaMemberderm:AssetPurchaseAgreementMember2021-03-310001867066derm:AccutaneMemberderm:LicenseAndSupplyAgreementWithDrlMember2020-07-310001867066derm:AccutaneMemberderm:LicenseAndSupplyAgreementWithDrlMember2020-07-012020-07-310001867066us-gaap:OperatingSegmentsMemberderm:DermatologicalSegmentMember2026-01-012026-03-310001867066us-gaap:OperatingSegmentsMemberderm:DermatologicalSegmentMember2025-01-012025-03-310001867066derm:AnniversaryTwoYearMemberderm:ZilxiMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryTwoYearMemberderm:AmzeeqMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryThreeYearMemberderm:ZilxiMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryThreeYearMemberderm:AmzeeqMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryOneYearMemberderm:ZilxiMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryOneYearMemberderm:AmzeeqMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryFourYearMemberderm:ZilxiMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryFourYearMemberderm:AmzeeqMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryFiveYearMemberderm:ZilxiMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:AnniversaryFiveYearMemberderm:AmzeeqMemberderm:VyneProductAcquisitionAgreementMember2022-01-012022-01-310001867066derm:QbrexzaMemberderm:AssetPurchaseAgreementMember2021-03-012021-03-3100018670662026-03-3100018670662025-12-310001867066us-gaap:CommonClassAMember2026-05-120001867066derm:CommonExcludingClassMember2026-05-1200018670662026-01-012026-03-31xbrli:sharesiso4217:USDutr:sqftxbrli:purederm:customerderm:itemiso4217:USDxbrli:sharesderm:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n​\n\n**FORM ****10-Q**\n\n(Mark one)\n\n​\n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n​\n\n**For the quarterly period ended****March 31, 2026**\n\n​\n\nOR\n\n​\n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n​\n\nFor the transition period from _________ to _________\n\n​\n\nCommission File Number: 001-41063\n\n​\n\n**JOURNEY MEDICAL CORPORATION**\n\n(Exact name of registrant as specified in its charter)\n\n​\n\n**Delaware**\n\n  ​ ​ ​\n\n**47-1879539**\n\n(State or other jurisdiction of incorporation or organization)\n\n(I.R.S. Employer Identification No.)\n\n​\n\n**9237 E Via de Ventura Blvd.****,****Suite 105****,****Scottsdale****,****AZ********85258**\n\n(Address of principal executive offices and zip code)\n\n​\n\n**(****480****)****434-6670**\n\n(Registrant’s telephone number, including area code)\n\n​\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n**Title of each class**\n\n  ​ ​ ​\n\n**Trading Symbol(s)**\n\n  ​ ​ ​\n\n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share\n\nDERM\n\nNASDAQ Capital Market\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n​\n\nIndicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n​\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge Accelerated Filer\n\n☐\n\nAccelerated Filer\n\n☐\n\nNon-accelerated Filer\n\n☒\n\nSmaller Reporting Company\n\n☒\n\nEmerging growth company\n\n☒\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n​\n\nIndicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n​\n\nIndicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.\n\n​\n\n**Class of Common Stock**\n\n  ​ ​ ​\n\n**Outstanding Shares as of May 12, 2026**\n\nCommon Stock Class A, $0.0001 par value\n\n6,000,000\n\nCommon Stock, $0.0001 par value\n\n​\n\n21,534,547\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nJOURNEY MEDICAL CORPORATION\n\n**Quarterly Report on Form 10-Q**\n\nTABLE OF CONTENTS\n\n[PART I.](#PARTIFINANCIALINFORMATION_392973)\n\n[FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_392973)\n\n  ​ ​ ​\n\n[Item 1.](#Item1UnauditedCondensedConsolidatedFinan)\n\n[Condensed Consolidated Financial Statements (unaudited)](#Item1UnauditedCondensedConsolidatedFinan)\n\n​\n\n1\n\n[Item 2.](#Item2ManagementsDiscussionandAnalysisofF)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF)\n\n​\n\n18\n\n[Item 3.](#Item3QuantitativeandQualitativeDisclosur)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n​\n\n24\n\n[Item 4.](#Item4ControlsandProcedures_557681)\n\n[Controls and Procedures](#Item4ControlsandProcedures_557681)\n\n​\n\n24\n\n​\n\n​\n\n​\n\n​\n\n[PART II.](#PartIIOtherInformation_588127)\n\n[OTHER INFORMATION](#PartIIOtherInformation_588127)\n\n​\n\n[Item 1.](#Item1LegalProceedings_280722)\n\n[Legal Proceedings](#Item1LegalProceedings_280722)\n\n​\n\n25\n\n[Item 1A.](#Item1ARiskFactors_809963)\n\n[Risk Factors](#Item1ARiskFactors_809963)\n\n​\n\n25\n\n[Item 2.](#Item2UnregisteredSalesofEquitySecurities)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities)\n\n​\n\n25\n\n[Item 3.](#Item3DefaultsofSeniorSecurities_794169)\n\n[Defaults Upon Senior Securities](#Item3DefaultsofSeniorSecurities_794169)\n\n​\n\n25\n\n[Item 4.](#Item4MineSafetyDisclosures_502614)\n\n[Mine Safety Disclosures](#Item4MineSafetyDisclosures_502614)\n\n​\n\n25\n\n[Item 5.](#Item5OtherInformation_192618)\n\n[Other Information](#Item5OtherInformation_192618)\n\n​\n\n25\n\n[Item 6.](#Item6Exhibits_315243)\n\n[Exhibits](#Item6Exhibits_315243)\n\n​\n\n26\n\n \n\n​\n\n \n\n[SIGNATURES](#SIGNATURES_511388)\n\n​\n\n27\n\n​\n\n​\n\n​\n\ni\n\n[Table of Contents](#TOC)\n\nPART I.      FINANCIAL INFORMATION"}